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Abstract 16 
Myostatin plays a negative role in skeletal muscle growth regulation but its potential 17 
role in the ovary has received little attention. Here, we first examined relative 18 
expression of myostatin (MSTN), myostatin receptors (ACVR1B, ACVR2B and 19 
TGFBR1) and binding protein, follistatin (FST), in granulosa (GC) and theca (TC) cells 20 
of developing bovine follicles. Secondly, using primary GC and TC cultures, we 21 
investigated whether myostatin affects steroidogenesis and cell number. Thirdly, effects 22 
of gonadotropins and other intrafollicular factors on MSTN expression in GC and TC 23 
were examined. MSTN, ACVR1B, TGFBR1, ACVR2B and FST mRNA was detected 24 
in both GC and TC at all follicle stages. Immunohistochemistry confirmed follicular 25 
expression of myostatin protein. Interestingly, MSTN mRNA expression was lowest in 26 
GC of large estrogen-active follicles while GC FST expression was maximal at this 27 
stage. In GC, myostatin increased basal CYP19A1 expression and estradiol secretion 28 
whilst decreasing basal and FSH-induced HSD3B1 expression and progesterone 29 
secretion and increasing cell number. Myostatin also reduced IGF-induced progesterone 30 
secretion. FSH and dihydrotestosterone had no effect on granulosal MSTN expression 31 
whilst insulin-like growth factor and tumour necrosis factor-alpha suppressed MSTN 32 
level. In TC, myostatin suppressed basal and LH-stimulated androgen secretion in a 33 
follistatin-reversible manner and increased cell number, without affecting progesterone 34 
secretion. LH reduced thecal MSTN expression whilst BMP6 had no effect. 35 
Collectively, results indicate that, in addition to being potentially responsive to muscle-36 
derived myostatin from the circulation, myostatin may have an intra-ovarian 37 
autocrine/paracrine role to modulate thecal and granulosal steroidogenesis and cell 38 
proliferation/survival.   39 
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Introduction 40 
Ovarian follicle development is dependent on the actions and interactions of systemic 41 
and intra-ovarian regulatory signals. Whilst pituitary gonadotrophins (FSH, LH) are the 42 
key endocrine signals driving follicle development, a complex array of locally-produced 43 
growth factors also contribute to the modulation of follicular somatic cell proliferation 44 
and differentiation, ‘initial’ and ‘cyclic’ follicle recruitment, steroidogenesis, dominant 45 
follicle selection and ovulation (Campbell et al. 2003, Webb et al. 2003). Prominent 46 
amongst these are various members of the transforming growth factor-β (TGF-β) 47 
superfamily including growth and differentiation factor-9 (GDF9), anti-mullerian 48 
hormone (AMH), inhibins, activins and several bone morphogenetic proteins (BMP) 49 
including BMP2, BMP4, BMP6 and BMP7 (Shimasaki et al. 2004, Knight & Glister 50 
2006). In the present study we examined the potential involvement of another TGF-β 51 
superfamily member, myostatin (also known as GDF8) in regulating ovarian follicle 52 
function.  53 
Myostatin is well-recognised for its negative autocrine/paracrine role in skeletal muscle 54 
development (Otto & Patel 2010, Schiaffino et al. 2013). Myostatin-null mice show a 55 
pronounced increase in muscle mass due to muscle fibre hyperplasia and hypertrophy 56 
(McPherron et al. 1997). Naturally occurring inactivating mutations in the myostatin 57 
gene are also evident in several species including bovine (Kambadur et al. 1997), ovine 58 
(Clop et al. 2006), canine (Mosher et al. 2007) and human (Schuelke et al. 2004) and 59 
these also display a phenotype of substantially increased muscle mass. Conversely, 60 
upregulation of myostatin is associated with pathological conditions characterised by 61 
muscle wasting, notably sarcopenia and cachexia arising from late-stage cancer, chronic 62 
kidney failure and congestive heart failure (Elkina et al. 2011, Elliott et al. 2012). 63 
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Apart from skeletal muscle, myostatin has also been implicated in the regulation of 64 
cardiomyocyte and adipocyte function (review: (Elliott et al. 2012)), Moreover, 65 
investigations into the expression and potential functional role(s) of myostatin in 66 
reproductive organs including the human ovary have recently been reported (Chang et 67 
al. 2015, Fang et al. 2015, Chang et al. 2016a, Chang et al. 2016b).  68 
Myostatin signals through the activin receptor type 2B (ACTR2B), forming a signalling 69 
complex with ACVR1B (ALK4) and/or TGFBR1(ALK5) that activates an intracellular 70 
Smad 2/3-dependent signal transduction pathway. Myostatin receptor activation can 71 
also signal in a Smad-independent manner via activation of MAPK and inhibition of 72 
Akt pathways (Rebbapragada et al. 2003). Binding of myostatin to its signalling 73 
receptors is modulated by follistatin (Amthor et al. 2004). Follistatin was initially 74 
identified as a secreted activin-binding protein but has since been shown to bind several 75 
other TGF-β ligands including BMP-2,-4,-6 and -7 (Fainsod et al. 1997, Iemura et al. 76 
1998, Glister et al. 2004). Follistatin-null mice show decreased muscle mass (Matzuk et 77 
al. 1995) likely arising from diminished antagonism of myostatin signalling. Conversely, 78 
transgenic overexpression of follistatin promotes a hypermuscular phenotype 79 
resembling that of myostatin-null mice (Lee & McPherron 2001).  80 
Global microarray studies of the bovine ovary revealed that myostatin mRNA is 81 
expressed in follicular granulosa (Skinner et al. 2008, Glister et al. 2014, Hatzirodos et 82 
al. 2014b) and theca cells (Glister et al. 2013, Hatzirodos et al. 2014a) although studies 83 
to confirm expression and explore the potential functional role(s) of myostatin in the 84 
bovine ovary have not been reported. Myostatin mRNA expression has also been 85 
documented in human reproductive tissues including ovary (Chang et al. 2015), 86 
myometrium (Islam et al. 2014) and trophoblast (Peiris et al. 2014) and recent evidence 87 
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from studies on luteinized granulosa cells supports various functional roles. For instance, 88 
treatment of human granulosa-lutein cells with myostatin down-regulated expression of 89 
steroidogenic acute regulatory protein (STAR) and reduced progesterone secretion, 90 
whilst increasing cytochrome P450 aromatase (CYP19A1) expression, FSHR 91 
expression and estradiol secretion (Chang et al. 2015, Fang et al. 2015, Chang et al. 92 
2016a). An anti-proliferative effect of myostatin on human granulosa-lutein cells was 93 
also reported (Chang et al. 2016b). To our knowledge, there have been no reports on 94 
effects of myostatin on non-luteinized granulosa cells, nor on theca cells from any 95 
species. 96 
Given the paucity of information on the ovarian expression and possible intraovarian 97 
role(s) of myostatin, particularly in relation to actions on non-luteinized follicular cells, 98 
the aims of the present study were to: (1) examine mRNA expression profiles for 99 
myostatin, its signalling receptors and binding protein (follistatin; FST) in granulosa 100 
(GC) and theca (TC) cells across different stages of bovine antral follicle development; 101 
(2) use non-luteinized bovine GC and TC culture models to investigate whether 102 
myostatin affects steroid production; (3) determine whether the effect of myostatin can 103 
be attenuated by follistatin; (4) investigate whether thecal and granulosal expression of 104 
myostatin mRNA is modulated by gonadotropins and several intrafollicular factors 105 
implicated in the regulation of follicular steroidogenesis. 106 
 107 
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Materials and Methods 108 
Relative expression of myostatin, follistatin and myostatin receptor mRNAs in 109 
developing bovine antral follicles. 110 
Relative mRNA expression for myostatin (MSTN), myostatin receptors (ACVR2B, 111 
ACVR1B and TGFBR1) and follistatin (FST) in theca and granulosa layers from 112 
bovine antral follicles was determined using RT-qPCR. Ovaries from randomly cycling 113 
cattle were obtained from an abattoir (Anglo Beef Processors, Guildford, UK) and 114 
selected for follicle dissection as described previously (Glister et al 2001; 2004; 2010). 115 
Briefly, antral follicles of diameter 3-18mm were dissected out and sorted by size into 116 
small (3-6mm; n = 30), medium (7-10mm; n = 43) and large (11-18mm; n = 37) 117 
categories. For each follicle GC and TC layers were retrieved for RNA extraction and 118 
follicular fluid recovered for steroid hormone analysis. Follicles in the large (11-18mm) 119 
category were subdivided retrospectively into large estrogen-active (LEA; E:P ratio >1) 120 
and large estrogen-inactive (LEI; E:P ratio <1) categories according to their 121 
intrafollicular ratio of estrogen to progesterone (E:P ratio). Isolated GC and TC were 122 
homogenised in 0.5ml of Tri reagent (Sigma UK Ltd, Poole) and stored at -80
0
C for 123 
subsequent RNA purification. The number of GC and TC RNA extracts recruited to the 124 
study (n = 82 GC samples; n = 87 TC samples; see fig. 1 for n-values for individual 125 
follicle categories) was lower than the number of extracts processed because samples 126 
indicating >5% GC/TC cross contamination were rejected during an initial quality 127 
control screen.  This involved a RT-qPCR-based comparison of relative transcript 128 
abundance of four GC/TC-specific ‘marker’ transcripts (FSHR and CYP19A1 for GC, 129 
CYP17A1 and INSL3 for TC) each normalized to β-actin transcript abundance (data not 130 
shown).  131 
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Primary granulosa and theca cell culture models 132 
Ovaries from randomly cycling cattle were collected from a local abattoir. As described 133 
previously (Glister et al. 2001, Glister et al. 2005) GC and TC were isolated from 4-134 
6mm diameter follicles, plated out in either 96-well (75,000 cells/well; for steroid 135 
secretion experiments) or 24-well (250,000 cells/well; for RNA extraction experiments) 136 
plates and cultured for 7 days.  To preserve a non-luteinized cellular phenotype 137 
(Gutierrez et al. 1997, Campbell et al. 1998, Glister et al. 2001, Glister et al. 2005, 138 
Sahmi et al. 2006) chemically-defined serum-free media was used throughout the 139 
culture period. This consisted of McCoy’s 5A modified medium supplemented with 1% 140 
(v/v) antibiotic-antimycotic solution, 10 ng/ml bovine insulin, 2 mM L-glutamine, 10 141 
mM Hepes, 5 µg/ml apotransferrin, 5 ng/ml sodium selenite, 0.1% BSA. In the case of 142 
GC cultures, media was also supplemented with 10
-7
 M androstenedione as aromatase 143 
substrate (all media and supplements were purchased from Sigma).  Media were 144 
replenished and treatments added on days 2 and 4 (see below). Cultures were terminated 145 
on day 7 when conditioned media were retained for hormone assays and viable cell 146 
number was determined by neutral red uptake assay as described elsewhere (Glister et 147 
al. 2001) 148 
Effects of myostatin on granulosal and thecal steroid secretion and viable cell 149 
number 150 
Recombinant human myostatin (R&D Systems; 94% amino acid sequence homology 151 
with bovine myostatin) was added to wells to give final concentrations of 0.08, 0.4, 2, 152 
10, 50 and 100ng/ml in the presence and absence of gonadotropin (FSH or LH). Highly 153 
purified ovine FSH (oFSH 19SIAPP) and LH (oLH-S-16) were provided by the NHPP 154 
(Torrance, CA, USA). In GC cultures, FSH was used at a final concentration of 0.3 155 
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ng/ml, shown previously to elicit optimal estradiol secretion (Glister et al. 2001, Glister 156 
et al. 2004). GC were also treated with myostatin (100ng/ml) in the presence and 157 
absence of LR3 IGF-1 analogue (Sigma;10 and 50 ng/ml) since IGF-1 is also a potent 158 
stimulator of estradiol secretion (Gutierrez et al. 1997, Glister et al. 2001). In the case 159 
of TC cultures, LH was used at a final concentration of 150 pg/ml, shown previously to 160 
elicit maximal androstenedione secretion (Glister et al. 2005). Control wells received an 161 
equivalent volume of culture medium as vehicle. 162 
 163 
Can follistatin neutralize the effect of myostatin on thecal androstenedione secretion? 164 
To examine whether follistatin can neutralize the suppressive effects of myostatin on 165 
thecal androgen secretion, TC were treated with myostatin (100ng/ml) in the 166 
presence/absence of recombinant human follistatin-288 (R&D systems; 96% amino acid 167 
sequence homology with bovine follistatin) at 0.25 and 1.25µg/ml. These 168 
concentrations were shown previously to reverse the effects of 50 ng/ml activin and 169 
BMP6 on bovine GC (Glister et al. 2004). 170 
 171 
Effect of myostatin on granulosal expression of steroidogenic pathway components 172 
To evaluate the effects of myostatin on expression of key transcripts involved in 173 
steroidogenesis (CYP11A1, HSD3B1, CYP19A1, FSHR) GC were cultured in 24-well 174 
plates (250,000 cells/well) and exposed to fixed concentrations of myostatin (100 175 
ng/ml) in the presence and absence of an optimal concentration of FSH (300 pg/ml). At 176 
the end of culture, media were removed and cell lysates were prepared for total RNA 177 
extraction and RT-qPCR analysis. 178 
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 179 
Do gonadotropins and other factors modulate MSTN expression by cultured GC and 180 
TC? 181 
GC (n> 4 independent batches of cells) plated out in 24-well plates were cultured in the 182 
presence/absence of FSH (300 pg/ml) and several other intrafollicular factors shown 183 
previously to modulate steroidogenesis at the concentrations used here, including LR3 184 
IGF-1 analogue at 10 ng/ml (Glister et al. 2001), TNFα at 10 ng/ml (Glister et al. 2014) 185 
and DHT at 100nM (Wu et al. 2011, Hasegawa et al. 2017). RNA was harvested at the 186 
end of culture for evaluation of relative gene expression by RT-qPCR. TC (n=9 187 
independent batches of cells) plated out in 96-well plates were treated with LH (150 188 
pg/ml) in the presence/absence of BMP6 (10 ng/ml) shown previously to suppress 189 
thecal androgen production (Glister et al. 2005, Glister et al. 2013).  190 
 191 
 RNA isolation, cDNA synthesis and real-time PCR 192 
Total RNA was isolated using Tri-reagent as described previously (Glister et al. 2010). 193 
cDNA was synthesized from 1µg of RNA using the AB High Capacity cDNA synthesis 194 
kit (Thermo Fisher Scientific; used according to manufacturers protocol) in a 20µl 195 
reaction primed with random hexamers. PCR primers (see table 1) were designed using 196 
Primer-BLAST' (http://www.ncbi.nlm.nih.gov/tools/primer-blast) with BLAST 197 
specificity checking against all known bovine (Bos taurus) transcripts to exclude 198 
potential amplification of off-target sequences. Primer pairs were also validated using 199 
agarose gel electrophoresis to demonstrate amplification of a single product of the 200 
predicted size. Melt curve analyses was included in each PCR assay to confirm the 201 
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amplification of a single product in each sample. cDNA template log-dilution curves 202 
were used to demonstrate satisfactory PCR efficiency and linearity. PCR assays were 203 
carried out in a volume of 14µl containing 5µl cDNA template, 1µl each forward and 204 
reverse primers (final concentration 0.36µM) and 7µl QuantiTect SYBR Green QPCR 205 
2x Master Mix (Qiagen, Crawley, W. Sussex, UK). Samples were processed on a 206 
StepOne Plus thermal cycler (Applied Biosystems) with cycling conditions: 15min at 207 
95
o
C (one cycle only) followed by 15s at 95
o
C and 1min at 60
o
C for 40 cycles. The 208 
∆∆Ct method (Livak & Schmittgen 2001) was used to compare the relative abundance 209 
of each mRNA transcript. Ct values for each transcript in a given sample were first 210 
normalized to the corresponding ß-actin Ct value (i.e. ∆Ct value).  In the case of theca 211 
and granulosa tissue samples ∆Ct values for each transcript in a given sample were then 212 
normalized to the mean ∆Ct value for that transcript in all tissue samples. Resultant 213 
∆∆Ct values were converted to fold-differences using the formula: fold-difference = 2 
(-214 
∆∆Ct).
 In the case of cell culture experiments ∆Ct values were normalized to the 215 
corresponding ∆Ct value for vehicle-treated control cells. ∆∆Ct values were then 216 
converted to fold-differences using the formula: fold-difference = 2 
(-∆∆Ct).
  217 
 218 
Steroid hormone assays 219 
Steroid concentrations were determined by competitive ELISA as described previously 220 
(Glister et al. 2010, Glister et al. 2013, Glister et al. 2014). The progesterone assay had 221 
a detection limit of 20pg/ml and intra- and inter-assay CVs were 8% and 10% 222 
respectively. The androstenedione ELISA had a detection limit of 30 pg/ml and intra- 223 
and inter-assay CVs were 7% and 10% respectively. The estradiol ELISA had a 224 
detection limit of 15 pg/ml and intra- and inter-assay CVs were 6% and 9% respectively.  225 
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 226 
Immunohistochemistry 227 
Bovine ovaries were dissected into segments and fixed in formalin for 48 hours, before 228 
being dehydrated through an alcohol series, embedded in wax and sectioned (5µm) onto 229 
Superfrost charged slides (VWR, Lutterworth, UK). Sections were dewaxed and 230 
rehydrated prior to boiling in citrate buffer (10mM citric acid, pH6.0), blocking of 231 
endogenous peroxidase (3% H202 in methanol) and blocking of nonspecific binding 232 
with 20% normal goat serum (NGS, Vector Laboratories Ltd, Peterborough, UK). After 233 
this, sections were incubated overnight at 4°C in rabbit antibody against GDF8 (1:200; 234 
sc-28910, Santa Cruz) diluted in 2% NGS. Control sections were incubated with normal 235 
rabbit serum (1:200) diluted in 2% NGS. Primary antibody binding was detected using 236 
biotinylated goat anti-rabbit diluted 1:250 in 2% NGS and Vector Elite ABC reagents 237 
(Vector), prepared as per manufacturers instructions. Visualization of bound antibodies 238 
was achieved using 3,3’–diaminobenzidine tetrahydrochloride (DAB; Vector), prior to 239 
slides being counterstained with haematoxylin, dehydrated through an alcohol series 240 
and mounted with coverslips using DPX mounting medium. Sections were imaged 241 
using a Zeiss Axioscop 2 microscope and AxioCam digital camera. 242 
 243 
Statistical analysis 244 
Steroid concentrations were log-transformed prior to statistical analysis to reduce 245 
heterogeneity of variance. RT-qPCR data were analysed as ∆∆Ct values (i.e. log 2 246 
values) before conversion to fold-difference values for graphical presentation of relative 247 
transcript abundance. ACTB was used as the normalization control and showed uniform 248 
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expression level across experimental groups being compared. Results were evaluated 249 
using one- and/or two-way ANOVA and, where indicated, post-hoc pairwise 250 
comparisons were made using Fisher’s protected least significant difference (PLSD) test. 251 
Results of cell culture experiments are based on a minimum of three replicate 252 
experiments using independent batches of cells (see figure legends for numbers of 253 
replicates) 254 
 255 
Results 256 
 257 
Relative expression of myostatin, follistatin and myostatin receptors in theca and 258 
granulosa layers 259 
Myostatin 260 
MSTN mRNA expression was found in both TC and GC of all antral follicles examined 261 
and overall expression level was higher in TC than GC (Figure 1A). Interestingly, while 262 
MSTN expression level in TC was uniform across antral follicle development, 263 
expression in GC fell ~15-fold to a nadir in large estrogen active (LEA) follicles. 264 
However, a higher expression level was maintained in GC of large estrogen inactive 265 
(LEI) follicle. (Fig. 1A). Immunohistochemistry confirmed myostatin protein 266 
expression in both TC and GC of antral follicles (Fig. 2). In addition myostatin 267 
immunoreactivity was evident in preantral follicles and in vascular smooth muscle cells. 268 
Both oocytes and granulosa cells of primordial, primary and secondary follicles 269 
exhibited positive immunostaining for myostatin (Fig 2) 270 
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Follistatin 271 
FST mRNA expression was found in both TC and GC at all stages of follicle 272 
development examined with much higher expression levels in GC than TC (Fig. 1B). 273 
Interestingly, the expression of FST in GC sharply increased in LEA follicles but 274 
remained low in LEI follicles; this was opposite to what was observed for MSTN. 275 
Myostatin receptors (ACVR2B, ACVR1B and TGFBR1) 276 
ACVR1B, TGFBR1 and ACVR2B mRNA expression was found in both TC and GC at 277 
all stages of follicle development examined. The expression of ACVR2B and ACVR1B 278 
was generally higher in GC than TC while TGFBR1 expression levels were broadly 279 
similar in the two cell types. No notable changes in cell-specific patterns of expression 280 
of these receptors between each stages of follicle development were evident (Fig. 281 
1C,D,E respectively).  282 
 283 
Effect of myostatin on basal and FSH-induced steroid secretion by GC 284 
Myostatin promoted a marked increase in basal estradiol secretion by cultured GC (~12-285 
fold; P<0.0001; Fig. 3A) but did not modulate the >30-fold increase in estradiol 286 
secretion elicited by FSH. Myostatin suppressed both basal (P<0.01) and FSH-induced 287 
(P<0.001) progesterone secretion (Fig. 3B). In addition, myostatin promoted a modest 288 
though significant increase in cell number under basal conditions (~20% increase; 289 
P<0.001), but not under FSH-stimulated conditions (Fig. 3C). 290 
 291 
Effects of myostatin on GC expression of steroidogenesis-related transcripts 292 
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The stimulatory action of myostatin on basal estradiol secretion was accompanied by a 293 
~10-fold increase in CYP19A1 expression level (P<0.05; Fig. 3D). Concomitantly, a 294 
reduction in CYP11A1 and HSD3B1 expression level was observed (P<0. 05; Fig. 3EF) 295 
that mirrored the myostatin-induced decrease in progesterone secretion. Myostatin did 296 
not affect FSHR expression (data not shown). 297 
 298 
Effect of myostatin on basal and IGF1-induced secretion of estradiol and 299 
progesterone by GC 300 
Fig.4 confirms the stimulatory effect of myostatin treatment (100 ng/ml) on basal 301 
estradiol secretion by GC. However, myostatin did not modulate the stimulatory effect 302 
of the LR3-IGF1 analogue on estradiol secretion or viable cell number.  Myostatin 303 
reduced both basal and IGF-induced progesterone secretion (P<0.05) but did not modify 304 
the IGF-induced increase in viable cell number. 305 
 306 
Effects of FSH, LR3 IGF-1, TNFα and DHT on expression of MSTN mRNA by 307 
cultured GC 308 
Fig. 5 shows that treatment of cultured GC with FSH elicited a ~50-fold upregulation of 309 
CYP19A1 expression (p<0.05) and estradiol secretion but did not affect MSTN 310 
expression. Treatment with IGF-1 analogue also promoted a marked increase in 311 
CYP19A1 expression (~10-fold; P<0.05) and estradiol secretion that was accompanied 312 
by a 60% reduction in MSTN expression (P<0.05). Treatment with TNFα had no effect 313 
on basal CYP19A1 expression but abolished FSH-induced upregulation of CYP19A1 314 
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expression and estradiol secretion. TNFα suppressed MSTN expression by ~80% 315 
(P<0.05) under both basal and FSH-stimulated conditions. Treatment with DHT did not 316 
affect expression of either MSTN or CYP19A1. 317 
Effects of myostatin on thecal steroid secretion and viable cell number 318 
Myostatin suppressed androstenedione secretion in a dose-dependent manner (P<0.001) 319 
with an IC50 of ~10 ng/ml under LH-stimulated conditions (Fig. 6A). No effect of 320 
myostatin on progesterone secretion was observed (Fig. 6B). Viable cell number was 321 
increased (~25%; P<0.0001) by myostatin under both basal and LH-stimulated 322 
conditions (Fig. 6C). LH increased both androstenedione and progesterone secretion but 323 
did not affect viable cell number. 324 
Can follistatin neutralize the effect of myostatin on androstenedione secretion? 325 
Treatment of cells with myostatin alone decreased androstenedione secretion by ~80% 326 
(P<0.000; Fig. 7). Co-treatment with follistatin partially reversed this inhibitory action 327 
(P<0.001). Treatment with follistatin alone tended to increase androstenedione secretion 328 
but the effect was not statistically significant.  329 
 330 
Effects of LH and BMP6 on MSTN mRNA expression by cultured TC  331 
Fig. 8 shows that treatment of cultured TC with LH elicited a 4-fold increase in 332 
CYP17A1 expression and androstenedione secretion that was accompanied by a 40% 333 
suppression of MSTN expression (p<0.05). Treatment with BMP6 profoundly 334 
suppressed basal and LH-induced CYP17A1 expression and androstenedione secretion. 335 
Whilst BMP6 alone did not affect MSTN expression, it reversed the suppressive effect 336 
of LH on MSTN expression. 337 
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 338 
Discussion 339 
 340 
In this study, we first provide novel information on the spatio-temporal pattern of 341 
mRNA expression of myostatin, its signalling receptors and the binding protein (FST), 342 
at different stages of bovine antral follicles development. Expression of mRNA for 343 
MSTN and its receptors was found in both GC and TC at all antral follicle stages 344 
examined, consistent with and extending previous evidence from global microarray 345 
studies (Skinner et al. 2008, Glister et al. 2013, Glister et al. 2014, Hatzirodos et al. 346 
2014a, Hatzirodos et al. 2014b). Immunohistochemistry confirmed corresponding 347 
expression of myostatin protein in follicular granulosa and theca interna layers of antral 348 
follicles. Moreover, myostatin immunoreactivity was observed at earlier follicle stages 349 
than those we analysed for mRNA expression, with positive staining in both oocytes 350 
and GC of primordial, primary and secondary follicles and both GC and TC of late 351 
preantral and early antral follicles. The inverse mRNA expression pattern of MSTN and 352 
FST we observed in GC of large estrogen-active follicles is of interest since follistatin is 353 
known to bind to and inhibit myostatin signaling (Lee & McPherron 2001, Amthor et al. 354 
2004), a finding confirmed in this study by its ability to attenuate the effect of myostatin 355 
on thecal androgen production. These results suggest, therefore, that GC-derived 356 
myostatin and follistatin interact to regulate ovarian follicle physiology. In particular, 357 
these observations suggest that autocrine/paracrine signalling by GC-derived myostatin 358 
is attenuated in large healthy follicles (i.e. low myostatin/high follistatin), such as those 359 
reaching the preovulatory stage of development. By contrast, at earlier antral follicle 360 
stages (i.e. high myostatin/low follistatin), myostatin signalling via a Smad 2/3 361 
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dependent pathway may contribute to the suppression of thecal androgen production 362 
whilst upregulating granulosal estradiol production and down-regulating progesterone 363 
production. Thus, myostatin appears to act to prevent/delay premature follicle 364 
maturation and luteinisation in a similar manner to that suggested previously for 365 
activins and BMPs  (Findlay et al. 2002, Knight & Glister 2006), both of which can 366 
attenuate thecal androgen production, enhance granulosal estrogen output whilst 367 
suppressing granulosal progesterone output.  368 
The present results from experiments on non-luteinized ovarian cell models clearly 369 
support the above with myostatin suppressing androgen secretion by theca cells. In the 370 
case of granulosa cells, myostatin enhanced basal CYP19A1 expression and estradiol 371 
secretion whilst suppressing CYP11A1 and HSD3B1 expression and secretion of 372 
progesterone. In addition, treatment of human granulosa-lutein cells with myostatin was 373 
recently reported to enhance FSH-induced upregulation of aromatase/estradiol 374 
production, while inhibiting LH-induced upregulation of StAR/progesterone production 375 
(Chang et al. 2016a). Moreover, the present study found that myostatin increased viable 376 
cell number in both TC and GC cultures suggesting a positive effect on cell 377 
proliferation and/or survival. This finding contrasts with a report that myostatin reduces 378 
proliferation of human granulosa-lutein cells, evidently by upregulating connective 379 
tissue growth factor expression (Chang et al. 2016b). The reason for this discrepancy is 380 
not known but may reflect the effect of luteinisation, or a species difference. 381 
An intrafollicular IGF system is firmly implicated in the autocrine/paracrine regulation 382 
of follicle development, steroidogenesis and dominant follicle selection (Campbell et al. 383 
1995, Glister et al. 2001, Silva & Price 2002, Webb et al. 2003). Like FSH, IGF-1 can 384 
upregulate granulosal estradiol secretion; moreover, IGF-1 can augment follicular 385 
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responsiveness to FSH, providing a potential mechanism for selecting the dominant 386 
follicle from the cyclically-recruited growing cohort (Campbell et al. 1995, Webb et al. 387 
2003). It was therefore pertinent to investigate whether myostatin affected the GC 388 
response to IGF-1 treatment. Although the results showed no effect on IGF-induced 389 
estradiol production or cell number, myostatin increased basal estradiol production and 390 
cell number whilst reducing basal and IGF-induced progesterone production. As such, 391 
these observations further support the notion that myostatin has a role to delay 392 
premature follicle maturation and luteinisation. 393 
Whilst circulating or intrafollicular concentrations of myostatin in cattle have not been 394 
reported to our knowledge, serum concentrations of 10-20 ng/ml in cynomolgus 395 
monkey and human, ~24 ng/ml in rat and ~80 ng/ml in mouse have been documented 396 
(Furihata et al. 2016, Hedayati et al. 2016, Palandra et al. 2016). A myostatin 397 
concentration of ~3 ng/ml has been reported for human follicular fluid (Chen et al. 398 
2012). Since myostatin suppressed thecal androgen production and granulosal 399 
progesterone production in vitro with an IC50 value of ~10 ng/ml, it seems plausible 400 
that levels reaching the well-vascularized theca interna from peripheral blood could be 401 
sufficient to exert a regulatory action, regardless of the additional ‘local’ contribution 402 
(perhaps considerable?) of TC and/or GC-derived myostatin. On the other hand, given 403 
the greater diffusional barrier needed to reach the avascular granulosal layer, combined 404 
with the somewhat higher myostatin concentration (~50 ng/ml) needed to upregulate 405 
GC estradiol production, it is possible that GC are primarily responsive to locally 406 
produced myostatin acting in an autocrine/paracrine manner. The establishment of a 407 
bovine myostatin assay to allow comparison of endogenous concentrations in peripheral 408 
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blood and ovarian follicular fluid of cattle in different physiological states and in 409 
follicles at different stages of development, would be useful in this regard.  410 
As a first step towards investigating which endocrine and local paracrine and/or 411 
autocrine signals regulate myostatin expression in bovine ovarian follicles, we found 412 
that an LH-induced increase in thecal CYP17A1 expression and androstenedione 413 
secretion was accompanied by reduced MSTN expression level, consistent with a 414 
negative autocrine/paracrine action of myostatin on thecal androgen production, and 415 
with in the findings of our myostatin dose-response study. Indeed, it is possible that the 416 
stimulatory action of LH on thecal androgen production could be due, in part, to LH-417 
induced suppression of myostatin expression. The finding of a reduced MSTN mRNA 418 
abundance in TC producing more androgen could reflect increased androgen receptor-419 
mediated signalling since raised androgen levels are also associated with decreased 420 
MSTN expression in rat skeletal muscle tissue (Mendler et al. 2007). However, another 421 
intraovarian growth factor, BMP6, shown here and elsewhere (Glister et al. 2005, 422 
Glister et al. 2013) to greatly reduce thecal CYP17A1 expression and androstenedione 423 
secretion, did not affect thecal MSTN expression, casting doubt on androgen having a 424 
direct effect. Furthermore, treatment of cultured GC with the potent non-aromatisable 425 
androgen DHT had no effect on MSTN expression, suggesting an absence of androgen 426 
receptor-dependent regulation of granulosal MSTN expression.  Consistent with 427 
previous findings (Gutierrez et al. 1997, Glister et al. 2001) treatment of GC with FSH 428 
and IGF analogue both promoted substantial increases in estradiol secretion but only 429 
IGF analogue modulated MSTN expression, eliciting a ~60% reduction.  This suggests 430 
a possible interaction between IGF and myostatin signalling at the intrafollicular level 431 
that warrants further investigation. In skeletal muscle IGF-1 is a prominent positive 432 
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regulator of muscle cell proliferation and differentiation whilst myostatin opposes this 433 
action (Valdes et al. 2013). Despite this, IGF signalling upregulates myostatin 434 
expression in skeletal muscle tissue models, suggesting an inhibitory auto-regulatory 435 
loop (Yang et al. 2007, Kurokawa et al. 2009, Valdes et al. 2013). 436 
The pro-inflammatory cytokine, TNFα, is also expressed at the intraovarian level and is 437 
implicated in the regulation of follicle and luteal growth/regression and steroidogenesis 438 
(Sheldon et al. 2014, Samir et al. 2017). Consistent with earlier findings (Glister et al. 439 
2014) we showed that TNFα abolished FSH-induced upregulation of CYP19A1 and 440 
estradiol secretion by GC. This was accompanied by a marked reduction in MSTN 441 
expression reinforcing the view that myostatin has a positive role in granulosal estrogen 442 
production. In skeletal muscle models, activation of the TNFα pathway suppresses 443 
myogenesis but upregulates myostatin expression (Ono & Sakamoto 2017). Moreover, 444 
IGF can reverse the TNF-α induced suppression of myogenesis (Zhao et al. 2015) 445 
indicating interactions between positive (IGF1) and negative (myostatin, TNF-α) 446 
regulators of myogenesis. Further studies are needed to decipher the regulatory signals 447 
that contribute to the regulation of myostatin expression by ovarian follicular cells and 448 
to place these in a physiological context. 449 
With respect to myostatin-null mice, there are few, if any, references to their ovarian 450 
phenotype and the potential impact of the mutation on gonadal function and fertility is 451 
unknown to us. However, an in vivo study involving active immunization of female 452 
mice against myostatin, showed that the number of developing ovarian follicles in their 453 
female progeny was ~50% lower than that of control mice, with a similar diminution in 454 
litter size (Liang et al. 2007). Double-muscled cattle with myostatin mutations, 455 
reportedly show delayed puberty, reduced female fertility and a higher incidence of 456 
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dystocia and perinatal calf mortality/morbidity is associated with the large size of calves 457 
(McPherron & Lee 1997). However, we are not aware of any studies examining whether 458 
perturbations in ovarian follicle dynamics or steroidogenesis occur in double-muscled 459 
cattle. Whilst information is currently lacking on the above, it is possible that the 460 
physiological actions of myostatin in the ovary are functionally redundant owing to 461 
compensatory effects of other TGF-β ligands (e.g activins) that can signal via the same, 462 
or overlapping, receptors to elicit similar regulatory actions on theca and granulosa cells. 463 
In summary, this study provides novel information on the expression of myostatin, its 464 
signalling receptors and the binding protein, follistatin, in theca and granulosa cells of 465 
developing bovine antral follicles. Myostatin expression in GC declined to a very low 466 
level in large estrogen-active follicles in which expression of follistatin was maximal, 467 
suggesting attenuation of GC-derived myostatin signalling at this stage. Since myostatin 468 
suppressed thecal androgen production in a dose-dependent manner, an effect partially 469 
rescued by follistatin, it is hypothesised that attenuation of myostatin signalling in large 470 
antral follicles could facilitate thecal androgen production required as a substrate for 471 
granulosal aromatase enzyme and estrogen synthesis. Paradoxically, however, 472 
myostatin was found to promote CYP19A1 expression and estradiol production by 473 
granulosa cells under ‘basal’ conditions whilst suppressing CYP11A1 and HSD3B1 474 
expression and progesterone production (see Fig. 9). Taken together, this suggests a role 475 
for myostatin in delaying follicle progression towards pre-ovulatory maturation and 476 
luteinisation, in a manner similar to that suggested for granulosa-derived activin 477 
(Findlay et al. 2002, Knight & Glister 2006). Further in-depth studies in other species, 478 
including whole animal models, are required to confirm and extend these in vitro 479 
observations based on bovine ovarian cell culture models. It is also speculated that 480 
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muscle-derived myostatin conveyed to the ovary via the systemic circulation may 481 
contribute to the regulation of follicle function. In a similar manner, testicular 482 
steroidogenesis and gametogenesis may be influenced by circulating and/or locally-483 
produced myostatin although we are not aware of any studies, to date, examining this 484 
possibility. 485 
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 694 
Figure Legends 695 
Fig. 1. Relative abundance of mRNA transcripts for (A) MSTN, (B) FST, (C) 696 
ACVR1B, (D) TGFBR1 and (E) ACVR2B  in theca and granulosa layers of small (3-697 
6mm), medium (7-10mm) and large (11-18mm) bovine antral follicles. Large follicles 698 
are subdivided into estrogen active (E:P ratio >1) and estrogen-inactive (E:P ratio <1) 699 
categories referred to as LEA and LEI follicles, respectively. Intrafollicular E:P ratios 700 
for each follicle category are shown in panel F. Numbers in parenthesis in panel A are 701 
n-values for each group. Values are mean ± SEM and summarized two-way ANOVA 702 
results are shown. Within each cell type means without a common letter are 703 
significantly different (P<0.05). 704 
 705 
Fig. 2 Immunohistochemical staining of bovine ovary sections showing myostatin 706 
immunoreactivity (brown) in oocyte and granulosa cells of primordial (pF) and primary 707 
(PrF) follicles (A), secondary (SF) follicles (B,C) and in thecal (T) and granulosal (G) 708 
layers of antral follicles (AF) (D,E). Myostatin immunoreactivity was also evident in 709 
vascular smooth muscle cells (bv) (E). No staining was observed in control sections 710 
treated with normal rabbit serum instead of primary antibody (F). 711 
 712 
Fig. 3 Effect of myostatin on basal and FSH-induced secretion of (A) estradiol and (B) 713 
progesterone by bovine granulosa cells, and on (C) viable cell number; Panels (D-F) 714 
show the effect of myostatin ± FSH on expression of CYP19A1, CYP11A1 and 715 
HSD3B1 mRNA, respectively. Values are means ± sem (n = 5 independent cultures). 716 
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Results of 2-way ANOVA are summarized; *P<0.01, **P<0.01 ***P<0.001 compared 717 
to respective control with zero myostatin (panels A, B, C). In panels D-F means without 718 
a common letter are significantly different (P<0.05). 719 
  720 
 721 
Fig. 4 Effect of myostatin on basal and LR3 IGF-1-induced secretion of (A) estradiol 722 
and (B) progesterone by bovine granulosa cells and on (C) viable cell number. Values 723 
are means ± SEM (n = 3 independent cultures). Means without a common letter are 724 
significantly different (P<0.05). 725 
 726 
Fig. 5 Effect of different treatments known to modulate GC steroidogenesis on 727 
granulosal expression of (A) MSTN and (B) CYP19A1 and on (C) secretion of estradiol. 728 
Values are means ± SEM (n = 4 independent cultures); Means without a common letter 729 
are significantly different (p<0.05). 730 
 731 
Fig. 6 The effects of myostatin on basal and LH-induced secretion of (A) 732 
androstenedione and (B) progesterone by bovine theca cells. Panel (C) shows effects on 733 
viable cell number. Values are mean ± SEM (n=12 independent cultures); Two-way 734 
ANOVA p-values are shown 735 
 736 
Fig. 7 Ability of follistatin to antagonize myostatin-induced suppression of thecal 737 
androstenedione secretion. Values are means ± SEM (n=6 independent cultures) 738 
 739 
Fig. 8 Effect of LH and BMP6 on thecal expression of (A) MSTN and (B) 740 
CYP17A1and on (C) secretion of androstenedione. Values are means ± SEM (n = 8 741 
independent cultures); means without a common letter are significantly different 742 
(p<0.05). 743 
 744 
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 29
Fig. 9 Schematic diagram illustrating potential involvement of systemic and/or locally 745 
produced myostatin in the modulation of thecal and granulosal steroidogenesis.  746 
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Target 
 
Accession 
number 
 
Forward primer 
5' to 3' 
 
Reverse primer 
5' to 3' 
 
Amplicon 
size (bp) 
 
LHCGR NM_174381.1 ATTGCCTCAGTCGATGCCCAGACC AAAAAGCCAGCCGCGCTGC 92 
STAR NM_174189 TTTTTTCCTGGGTCCTGACAGCGTC ACAACCTGATCCTTGGGTTCTGCACC 103 
CYP11A1 NM_176644 CAGTGTCCCTCTGCTCAACGTCC TTATTGAAAATTGTGTCCCATGCGG 99 
HSD3B1 NM_174343.2 GCCACCTAGTGACTCTTTCCAACAGCG TGGTTTTCTGCTTGGCTTCCTCCC 111 
FSHR NM_174061.1 GCCAGCCTCACCTACCCCAGC AATTGGATGAAGGTCAGAGGTTTGCC 75 
CYP17A1 NM_174304 GACAAAGGCACAGACGTTGTGGTCA TGATCTGCAAGACGAGACTGGCATG 301 
CYP19A1 NM_174365 TCTGTCCCCACTGAATCCTCCTGG GGGTTTCATGGTGCTGTGTGGC 102 
MSTN NM_001001525.2  GTTCGATGTCCAGAGAGATGCCAGC ACTTGCGTTAGAAGATCAGACTCCGTGG  114 
ACTB NM_173979.3 ATCACCATCGGCAATGAGCGGTTC CGGATGTCGACGTCACACTTCATGA 128 
Table 1: List of primers used for quantitative RT-PCR  
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